TARS 241115 60.00P (TARS241115P60000) Stock Options, News & Quotes

US OptionsDetailed Quotes

TARS241115P60000

Watchlist

0.00
0.000.00%

15min DelayTrading Nov 8 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Earnings Preview: TARS to Report Financial Results Post-market on November 13
Moomoo NewsNov 7 20:00 ET
Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024
GlobeNewswireNov 6 16:30 ET
Tarsus Pharmaceuticals Seesaws Amid Report Alcon Interest Has Cooled
Seeking AlphaNov 6 12:38 ET
Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer
Globe NewswireNov 5 08:30 ET
Express News | Tarsus Appoints Elizabeth Yeu, M.d., as Chief Medical Officer
ReutersNov 5 08:30 ET
Press Release: Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer
Dow JonesNov 5 08:30 ET

Comments

MMu

Oct 29 15:16

$Tarsus Pharmaceuticals (TARS.US)$ wonder which 2 pharmas are bidding for Tarsus!!

Stock_Drift

Oct 28 04:33

Pre Market Ticks. 5:32am 10/28

$Jet.AI (JTAI.US)$ $ProShares UltraShort Bloomberg Crude Oil ETF (SCO.US)$ $Phunware (PHUN.US)$ $ImmunityBio (IBRX.US)$ $Longeveron (LGVN.US)$ $BIOSIG TECHNOLOGIES INC (BSGM.US)$ $Tarsus Pharmaceuticals (TARS.US)$ $XTL Biopharmaceuticals (XTLB.US)$ $LENZ Therapeutics (LENZ.US)$ $TC BioPharm (TCBP.US)$ $Top Wealth Group Holding (TWG.US)$ $Healthcare Triangle (HCTI.US)$ $Pixie Dust Technologies (PXDT.US)$
📊⚡️📊

Jaguar8

Aug 8 15:17

NEWS

$Tarsus Pharmaceuticals (TARS.US)$
Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
Tarsus Pharmaceuticals (NASDAQ: TARS) reported strong Q2 2024 financial results, with XDEMVY® net product sales reaching $40.8 million, a 65% increase from Q1.
Year-to-date sales totaled $65.5 million.
The company delivered over 37,000 bottles to patients in Q2 and achieved an impressive gross-to-net discount of 44%.
Tarsus expanded payer coverage, incl...

Moomoo AI

Mar 1 12:53

Analysts predict Tarsus Pharmaceuticals' growth to outpace the industry with a 5x annualised growth by 2024. The upgraded price target indicates an expected increase in the business's intrinsic value.

Analysts Are Upgrading Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Latest Results

Kevin Travers

Feb 27 10:02

Columns Biotechnology Stocks Climbing on Earnings and Test Results: What to Watch

$Viking Therapeutics (VKTX.US)$skyrocketed 77% after positive drug trial news Tuesday, leading to what proved to be a strong morning for pharmaceutical stocks.
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...